|
26 Oct 2020 |
HiFiBiO Therapeutics Completes First Cohort of a Phase I Study of its SARS-CoV-2 Neutralizing Antibody for the Treatment and Prevention of COVID-19
|
|
26 Oct 2020 |
CTA approval of BioInvent’s BI-1808, a first-in-class anti-TNFR2 antibody, sets stage for Phase I/IIa trial
|
|
26 Oct 2020 |
Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)
|
|
26 Oct 2020 |
GMAX Biopharm gives first does of anti-body drug treating PAH in phase 1B trial
|
|
26 Oct 2020 |
NBE-Therapeutics Commences First Clinical Study of Anti-ROR1 Antibody-Drug Conjugate for Patients with Solid Tumors
|
|
26 Oct 2020 |
Dupixent® (dupilumab) Late-breaking Pivotal Data Showing Significant Improvement in Eosinophilic Esophagitis Signs and Symptoms Presented for the First Time at Scientific Meetings
|
|
23 Oct 2020 |
First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca
|
|
23 Oct 2020 |
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
|
|
22 Oct 2020 |
Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of a Highly Effective Inhaled Treatment Supporting a Proposed Self-Administered Therapy for COVID-19 Patients
|
|
22 Oct 2020 |
Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T Cells
|
|
22 Oct 2020 |
Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine
|
|
21 Oct 2020 |
Chugai Enters into a License Agreement for Chugai’s Antibody Engineering Technologies with Novo Nordisk
|
|
21 Oct 2020 |
Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19
|
|
21 Oct 2020 |
Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS)
|
|
21 Oct 2020 |
Vir Biotechnology Presents New Data on VIR-2482, the Company’s Investigational Monoclonal Antibody for the Prevention of Influenza A, at IDWeek 2020
|
|
21 Oct 2020 |
Kineta Presents New Preclinical Data on its VISTA Antagonist Antibodies at the American Association for Cancer Research (AACR) Virtual Special Conference on Tumor Immunology and Immunotherapy
|
|
21 Oct 2020 |
NeuClone Announces Positive Results from Phase I Study of Stelara® (ustekinumab) Biosimilar Candidate
|
|
21 Oct 2020 |
Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease
|
|
19 Oct 2020 |
NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4
|
|
19 Oct 2020 |
Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)
|
|
19 Oct 2020 |
VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid Tumors
|
|
19 Oct 2020 |
U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Advanced Renal Cell Carcinoma
|
|
19 Oct 2020 |
Henlius and Essex Enter into a Global Co-Development and Exclusive License Agreement, to Jointly Develop Bevacizumab to Treat Ophthalmic Diseases
|
|
17 Oct 2020 |
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
|
|
17 Oct 2020 |
Janssen Receives CHMP Positive Opinion for Expanded Use of TREMFYA®▼ (guselkumab) in the Treatment of Active Psoriatic Arthritis (PsA) in the European Union (EU)
|
